title: Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy.
abstract: Androgen deprivation therapy (ADT) is a standard treatment for metastatic, recurrent and locally advanced prostate cancer (PCa). The aim of this study is to investigate the timing and extent of testosterone recovery in clinically localized PCa patients treated with radical prostatectomy (RP) and subsequent short-term adjuvant ADT. A total of 95 localized PCa patients underwent RP and 9-month adjuvant ADT were included in this prospective study. Serum testosterone level was measured before adjuvant ADT, at ADT cessation, and at 1, 3, 6, 9 and 12 months after cessation of ADT. A Cox proportional hazards model was used to assess variables associated with the time of testosterone normalization. The results showed that median patient age was 67 years and median testosterone level before adjuvant ADT was 361 (230-905) ng dl(-1). All patients finished 9-month adjuvant ADT and achieved castrate testosterone level. At 3 months after ADT cessation, testosterone recovered to supracastrate level in 97.9% patients and to normal level in 36.9% patients. The percentage of patients who recovered to normal testosterone level increased to 66.3%, 86.3% and 92.6% at 6, 9 and 12 months, respectively. Cox regression model found that higher baseline testosterone level (≥ 300 ng dl(-1)) was the only variable associated with a shorter time to testosterone normalization (hazard ratio: 1.98; P = 0.012). In conclusion, in most patients, testosterone recovered to supracastrate level at 3 months and to normal level at 12 months after 9-month adjuvant ADT cessation. Patients with higher baseline testosterone level need shorter time of testosterone normalization.
authors.affiliation: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Dai
authors.forename: Yuan-Yuan
authors.initials: YY
authors.lastname: Qu
authors.forename: Yun-Yi
authors.initials: YY
authors.lastname: Kong
authors.forename: Ding-Wei
authors.initials: DW
authors.lastname: Ye
authors.forename: Xu-Dong
authors.initials: XD
authors.lastname: Yao
authors.forename: Shi-Lin
authors.initials: SL
authors.lastname: Zhang
authors.forename: Hai-Liang
authors.initials: HL
authors.lastname: Zhang
authors.forename: Wei-Yi
authors.initials: WY
authors.lastname: Yang
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D015992:Body Mass Index; D003131:Combined Modality Therapy / Q000379:methods; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011183:Postoperative Complications / Q000453:epidemiology / Q000378:metabolism; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery; D020127:Recovery of Function; D012307:Risk Factors; D013739:Testosterone / Q000097:blood* / Q000172:deficiency*
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone